Literature DB >> 4683753

Idoxuridine in herpes simplex virus (type 1) encephalitis. Experience with 29 cases in Michigan, 1966 to 1971.

D C Nolan, C B Lauter, A M Lerner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4683753     DOI: 10.7326/0003-4819-78-2-243

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  9 in total

Review 1.  Perinatal and neonatal infections.

Authors:  J W Geme
Journal:  West J Med       Date:  1975-05

Review 2.  The contribution of virology to contemporary medicine.

Authors:  C Stuart-Harris
Journal:  Br J Prev Soc Med       Date:  1975-03

3.  Genital herpesvirus hominis infection in mice. I. Development of an experimental model.

Authors:  J C Overall; E R Kern; R L Schlitzer; S B Friedman; L A Glasgow
Journal:  Infect Immun       Date:  1975-03       Impact factor: 3.441

Review 4.  Herpes simplex virus infections of the central nervous system. Encephalitis and neonatal herpes.

Authors:  R J Whitley
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

5.  Herpes simplex encephalitis: treatment with surgical decompression and cytosine arabinoside.

Authors:  R K Laha; F W Saunders; W S Huestis
Journal:  Can Med Assoc J       Date:  1976-08-07       Impact factor: 8.262

6.  Editorial: Hepatitis and herpesvirus.

Authors: 
Journal:  Br Med J       Date:  1974-08-24

Review 7.  Infectious diseases: annual review of significant publications.

Authors:  H A Reimann
Journal:  Postgrad Med J       Date:  1974-08       Impact factor: 2.401

8.  Assessment of cytosine arabinoside as an antiviral agent in humans.

Authors:  C B Lauter; E J Bailey; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

9.  Iododeoxyuridine and herpesviral encephalitis: lack of inhibitory action against low-grade viral replication.

Authors:  G Plummer; A P Ingerson
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.